Drug intelligence / Profile preview

P-265

Development stage: Preclinical
Lead developer: Reig Jofre Group
Modality: Small Molecules
Administration: Topical

Overview

P-265 is a topical anti-infective candidate currently in the pipeline of Reig Jofre Group, specifically within its Specialty Pharmacare division. It is intended for the treatment of infectious skin conditions and is categorized as an antiseptic or topical anti-infective. As Reig Jofre is a pharmaceutical company focused on specialty products and generic formulations, P-265 likely represents a proprietary topical formulation, though its exact active ingredient and molecular mechanism of action remain undisclosed in public pipeline documentation.

Beyond the preview

Go deeper on P-265.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-265.

Explore the full profile